

September 26, 2024



Kane Biotech Announces Attendance at Upcoming Wound Care Conferences

WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) ("Kane Biotech", "Kane" or the "Company") announces that the Company will be showcasing its revyve™ Antimicrobial Wound Gel and revyve™ Antimicrobial Wound Gel Spray products at the following wound care conferences:

- Symposium on Advanced Wound Care (SAWC) (October 2-5, 2024 in Las Vegas Nevada) where Kane will be presenting research on the antibiofilm properties and compatibility with different dressings of revyve™ Antimicrobial Wound Gel. Both Kane's revyve™ Antimicrobial Wound Gel and revyve™ Antimicrobial Wound Gel Spray will be featured at US distributor ProgenaCare's booth throughout the conference.
- Wounds Canada National Hybrid Conference (October 17-19, 2024 in London, Ontario) where Kane will be presenting research on the Thermo-reversible Hydrogel to Target Wound Antibiotic Tolerant Biofilms with Prolonged Activity and will have a booth.
- Canadian Burn Conference (October 18-20, 2024 in Niagara-on-the-Lake, Ontario) where Kane will have a booth.
- Gulf Diabetic Foot Conference (November 15-16, 2024 in Kuwait City, Kuwait) where Kane will have a booth.

"These upcoming conferences will be a great opportunity for Kane to demonstrate the scientific benefits of the revyve™ product line to wound care practitioners and support our growing distribution network," said Marc Edwards, President & CEO. "We're committed to changing the wound care landscape and look forward to these meetings."

About Kane Biotech

Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (68 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol "KNBIF".

For more information:

Marc Edwards
Chief Executive Officer
Kane Biotech Inc
medwards@kanebiotech.com

Ray Dupuis
Chief Financial Officer
Kane Biotech Inc
rdupuis@kanebiotech.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane's: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at www.sedarplus.ca. Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.



Source: Kane Biotech Inc.